MissedCancerDiagnosis

Every oncologist understands the stage-dependent nature of cancer outcomes. Data from the National Cancer Institute SEER program makes the pattern explicit across cancers: colon cancer at Stage I has roughly 90% five-year survival; at Stage IV it drops to roughly 15%. Breast cancer follows a similar curve — 99% localized, 30% distant. Lung cancer is even more stark — 60%+ at early stages, under 10% at distant.

The biological mechanism is straightforward: earlier-stage cancers can be treated with less toxic therapies (surgery alone, in many cases), have higher cure rates, and leave patients with meaningfully longer life expectancy. Later-stage cancers require chemotherapy, radiation, targeted therapy, or immunotherapy, with higher treatment-related morbidity, more extensive surgery, and lower long-term survival.

This is why delayed-diagnosis cases can produce substantial damages even when the patient survives. A two-year delay in diagnosing a colon cancer that shifted from Stage I to Stage III means real, quantifiable differences in surgery, chemotherapy, recurrence risk, and five-year survival — differences that translate directly into economic and non-economic damages.

A handful of cancers account for the majority of missed-diagnosis litigation. Each has its own recognized standard-of-care framework and recurring failure patterns:

• Breast cancer. Missed or misread mammography, failure to investigate a palpable mass, inadequate follow-up on dense-breast findings. Commonly litigated because of the frequency of screening mammography and the volume of reads.
• Colon cancer. Failure to refer for colonoscopy when alarm symptoms are present (unexplained anemia, rectal bleeding, weight loss), missed lesions at colonoscopy, or failure to follow recommended screening intervals.
• Lung cancer. Missed nodules on chest imaging (often picked up incidentally), failure to recommend follow-up imaging on an indeterminate lesion, failure to investigate persistent symptoms in at-risk patients.
• Prostate cancer. Missed PSA elevations or inappropriate handling of rising PSA trends.
• Skin cancer (melanoma). Misdiagnosis of a concerning lesion as benign, failure to biopsy, or misread dermatopathology.
• Cervical cancer. Missed abnormal Pap smear or HPV test, failure to follow up on low-grade findings, inadequate colposcopy.

Less commonly litigated but equally serious: pancreatic, ovarian, bladder, kidney, and certain hematologic malignancies. Each has its own diagnostic standard that expert reviewers can compare against the records.

Delayed-diagnosis cases follow a small number of recurring patterns. Experienced plaintiff firms recognize these patterns in the records quickly:

Pattern 1: Alarm Symptoms Not Investigated

A patient reports a symptom that, in the appropriate clinical context, should prompt a workup for cancer. Rectal bleeding, unexplained weight loss, persistent cough in a smoker, a new palpable mass, dysphagia, hematuria, or a changing mole. The provider dismisses the symptom, attributes it to a benign cause without adequate workup, or fails to schedule the indicated testing. Months or years later, the cancer is found at a more advanced stage.

Pattern 2: Imaging or Pathology Misread

A diagnostic study shows a finding that should have been recognized — a nodule on a chest CT, a mass on a mammogram, an abnormal cell cluster on a biopsy — but was read as normal or “probably benign.” The patient is reassured, the follow-up is not scheduled, and the finding progresses. Expert review by a second radiologist or pathologist often confirms that the finding was present and should have been reported.

Pattern 3: Screening Skipped or Mistimed

The patient did not receive recommended screening — a colonoscopy after age 45, a mammogram at the recommended interval, a Pap smear, a low-dose chest CT for an at-risk smoker. The failure may reflect patient preference, access barriers, or provider oversight. Where the provider had a duty to recommend screening and did not, and where timely screening would have detected the cancer, a claim can follow.

Pattern 4: Abnormal Result Not Communicated or Followed Up

The test was done correctly, the finding was on the report, but the result was never communicated to the patient, or the follow-up was never scheduled. A positive stool test sitting in the chart unaddressed. An abnormal mammogram result that never triggered the recommended diagnostic imaging. A PSA elevation that the primary care physician meant to address at the next visit that never happened.

The standard of care for cancer diagnosis is built on several layers, each well-established in clinical literature and professional society guidelines:

• History and examination. Attention to family history, risk factors, and presenting symptoms. Physical examination appropriate to the complaint.
• Alarm-symptom workup. Systematic investigation when a symptom could indicate cancer — typically imaging, endoscopy, or tissue diagnosis depending on the organ system.
• Screening adherence. Following the screening recommendations from organizations like the U.S. Preventive Services Task Force, the American Cancer Society, and specialty societies. Appropriate adjustment for high-risk patients (family history, genetic predisposition).
• Diagnostic interpretation. Competent reading of imaging and pathology. When findings are equivocal, obtaining second opinions, recommending follow-up imaging, or proceeding to tissue diagnosis.
• Communication and follow-up. Ensuring that abnormal findings reach the patient, that follow-up is scheduled, and that the follow-up actually occurs. Closed-loop communication systems are increasingly standard in well-run practices.

A case becomes defensible as malpractice when an expert can identify a specific breach of one of these expectations and show that the breach caused the diagnostic delay.

Causation is often the hardest element in a missed cancer case. The defense will argue that the cancer was already advanced at the time of the alleged missed diagnosis, that earlier detection would not have altered the outcome, or that the patient’s specific tumor biology made the stage progression inevitable. Strong cases counter these arguments with specific evidence:

• Back-calculation of likely stage. A medical oncologist uses the growth kinetics of the specific cancer type, the timing of findings, and available imaging to estimate what stage the cancer was at when diagnosis should have been made.
• Stage-specific survival and treatment data. SEER and clinical trial data establish what outcomes would have been expected at the earlier stage.
• The patient’s specific tumor profile. Pathology, molecular markers, and imaging findings from the eventual diagnosis help refine the causation estimate.
• Comparative treatment profiles. The treatment the patient actually received (extensive surgery, chemotherapy, radiation) compared with what would have been indicated at the earlier stage (often surgery alone or with less-intensive adjuvant therapy).

Under Florida Statute § 766.102, a corroborating expert affidavit is required before filing. In missed cancer cases, that means an oncology expert willing to opine, in writing and under oath, that the delay caused measurable harm to a reasonable degree of medical certainty.

Damages in a missed cancer case are calculated against the counterfactual: what would the patient’s life have looked like if the diagnosis had been made on time? The difference between that counterfactual and the actual course is the compensable harm. Categories include:

• Past medical expenses. Every bill for the treatment of the more advanced cancer — surgeries, chemotherapy, radiation, hospitalizations, medications.
• Future medical expenses. Projected ongoing care for the patient’s remaining life — surveillance, survivorship care, treatment of recurrences, end-of-life care in fatal cases.
• Lost earnings. Documented missed work during the more extensive treatment course.
• Lost earning capacity. Where the treatment or the cancer itself reduced the patient’s long-term ability to work.
• Pain and suffering. For the more difficult treatment course, the reduced quality of life, the anxiety of reduced survival expectations. Uncapped in Florida after Kalitan (2017).
• Loss of consortium. Available to a spouse whose relationship with the patient was materially affected.
• Wrongful death damages. In fatal cases, recovery under Florida’s Wrongful Death Act for eligible survivors — spouse, minor children, dependent parents — for mental pain and suffering, loss of support, medical and funeral expenses, and lost net accumulations.

Florida Statute § 95.11(4)(b) governs medical malpractice limitations. The two-year discovery clock for missed cancer cases generally runs from when the patient learned — or reasonably should have learned — that the cancer was missed. For most patients, this is the date of the eventually-correct diagnosis.

The four-year outer limit from the negligent act is particularly consequential for cancers with longer latent periods. A missed diagnosis in 2022 that leads to a correct diagnosis in 2024 is within the two-year discovery window and the four-year outer limit. A missed diagnosis in 2018 with a correct diagnosis in 2024 may be outside the outer limit unless the fraud-or-concealment extension applies.

The 90-day pre-suit investigation and § 766.102 expert affidavit are mandatory before filing. These procedural requirements are treated seriously by Florida courts and cannot be bypassed.

If you or a family member received a cancer diagnosis that you suspect should have been made earlier — or if the cancer was found at a more advanced stage than you think it should have been — the next steps:

1. Continue your cancer treatment. Your oncology care is the priority. Do not delay treatment to pursue a legal claim.
2. Request all prior records. Primary care, specialist, imaging, and pathology records from the period before the correct diagnosis.
3. Preserve original imaging. Not just reports — the DICOM files. Experts need to see what was there to be seen.
4. Document symptoms and communications. When you reported symptoms, what the provider said, what follow-up was recommended or not.
5. Consult a Florida medical malpractice attorney. The consultation is free. A qualified firm will obtain the records, engage the right oncology and specialty experts, and tell you honestly whether the case meets Florida’s pre-suit requirements under § 766.102.

The statute of limitations matters. The strongest missed-cancer cases are those where records are pulled and evaluated within the first year after the correct diagnosis.